Modulators of resistant androgen receptor
US-2017320849-A1 · Nov 9, 2017 · US
Enzalutamide polymorphic forms and its preparation
US9701641B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9701641-B2 |
| Application number | US-201615292696-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 13, 2016 |
| Priority date | Sep 11, 2012 |
| Publication date | Jul 11, 2017 |
| Grant date | Jul 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application relates to crystalline and amorphous forms of Enzalutamide. The present application further relates to amorphous solid dispersions of Enzalutamide with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of Form R1 of Enzalutamide.
First claim
Opening claim text (preview).
The invention claimed is: 1. A process for preparing crystalline form R1 of enzalutamide characterized by a powder X-ray diffraction (PXRD) pattern having peaks at 12.3±0.2, 13.1±0.2, 15.0±0.2, and 17.5±0.2 degrees 2-theta, which comprises: a) providing a solution of enzalutamide in a single solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, n-butanol, acetic acid, tetrahydrofuran, toluene, methyl isopropyl ketone, dimethyl sulphoxide, methyl ethyl ketone, acetonitrile, ethyl acetate, xylene, N, N-dimethyl formamide, and N-methyl-2-pyrrolidone; and b) isolating crystalline enzalutamide form R1. 2. The process of claim 1 , wherein the isolation of crystalline form R1 in step b) is carried out by cooling, crash cooling, concentrating, adding an anti-solvent, and evaporation. 3. The process of claim 1 , wherein the single solvent is methanol. 4. The process of claim 1 , wherein the single solvent is isopropyl alcohol. 5. The process of claim 2 , wherein the anti-solvent is selected from water or n-heptane.
Assignees
Inventors
Classifications
- C07D233/86Primary
Oxygen and sulfur atoms, e.g. thiohydantoin · CPC title
Crystalline forms, e.g. polymorphs · CPC title
specific for metastasis · CPC title
- H04W12/06Primary
Authentication · CPC title
IP multimedia subsystem [IMS] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9701641B2 cover?
- The present application relates to crystalline and amorphous forms of Enzalutamide. The present application further relates to amorphous solid dispersions of Enzalutamide with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of Form R1 of Enzalutamide.
- Who is the assignee on this patent?
- Dr Reddys Laboratories Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D233/86. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).